Literature DB >> 12618525

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

Vera Eremina1, Manish Sood, Jody Haigh, András Nagy, Ginette Lajoie, Napoleone Ferrara, Hans-Peter Gerber, Yamato Kikkawa, Jeffrey H Miner, Susan E Quaggin.   

Abstract

Kidney disease affects over 20 million people in the United States alone. Although the causes of renal failure are diverse, the glomerular filtration barrier is often the target of injury. Dysregulation of VEGF expression within the glomerulus has been demonstrated in a wide range of primary and acquired renal diseases, although the significance of these changes is unknown. In the glomerulus, VEGF-A is highly expressed in podocytes that make up a major portion of the barrier between the blood and urinary spaces. In this paper, we show that glomerular-selective deletion or overexpression of VEGF-A leads to glomerular disease in mice. Podocyte-specific heterozygosity for VEGF-A resulted in renal disease by 2.5 weeks of age, characterized by proteinuria and endotheliosis, the renal lesion seen in preeclampsia. Homozygous deletion of VEGF-A in glomeruli resulted in perinatal lethality. Mutant kidneys failed to develop a filtration barrier due to defects in endothelial cell migration, differentiation, and survival. In contrast, podocyte-specific overexpression of the VEGF-164 isoform led to a striking collapsing glomerulopathy, the lesion seen in HIV-associated nephropathy. Our data demonstrate that tight regulation of VEGF-A signaling is critical for establishment and maintenance of the glomerular filtration barrier and strongly supports a pivotal role for VEGF-A in renal disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12618525      PMCID: PMC151905          DOI: 10.1172/JCI17423

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

Review 1.  The role of the podocyte in glomerulosclerosis.

Authors:  W Kriz; K V Lemley
Journal:  Curr Opin Nephrol Hypertens       Date:  1999-07       Impact factor: 2.894

2.  Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression.

Authors:  L A Bruggeman; S Dikman; C Meng; S E Quaggin; T M Coffman; P E Klotman
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

3.  The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy.

Authors:  L Barisoni; W Kriz; P Mundel; V D'Agati
Journal:  J Am Soc Nephrol       Date:  1999-01       Impact factor: 10.121

Review 4.  New aspects of podocyte cell biology.

Authors:  P Mundel; J Reiser
Journal:  Kidney Blood Press Res       Date:  1997       Impact factor: 2.687

5.  Multiple developmental roles of VEGF suggested by a LacZ-tagged allele.

Authors:  L Miquerol; M Gertsenstein; K Harpal; J Rossant; A Nagy
Journal:  Dev Biol       Date:  1999-08-15       Impact factor: 3.582

6.  Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165.

Authors:  S Gengrinovitch; B Berman; G David; L Witte; G Neufeld; D Ron
Journal:  J Biol Chem       Date:  1999-04-16       Impact factor: 5.157

7.  VEGF(165) mediates glomerular endothelial repair.

Authors:  T Ostendorf; U Kunter; F Eitner; A Loos; H Regele; D Kerjaschki; D D Henninger; N Janjic; J Floege
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

8.  Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells.

Authors:  R K Ganju; N Munshi; B C Nair; Z Y Liu; P Gill; J E Groopman
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  VEGF is required for growth and survival in neonatal mice.

Authors:  H P Gerber; K J Hillan; A M Ryan; J Kowalski; G A Keller; L Rangell; B D Wright; F Radtke; M Aguet; N Ferrara
Journal:  Development       Date:  1999-03       Impact factor: 6.868

10.  Vascular endothelial growth factor induces endothelial fenestrations in vitro.

Authors:  S Esser; K Wolburg; H Wolburg; G Breier; T Kurzchalia; W Risau
Journal:  J Cell Biol       Date:  1998-02-23       Impact factor: 10.539

View more
  425 in total

1.  Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered?

Authors:  Aernout Luttun; Peter Carmeliet
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

2.  Forced expression of vascular endothelial growth factor-A in podocytes decreases mesangial cell numbers and attenuates endothelial cell differentiation in the mouse glomerulus.

Authors:  Masahiro Suyama; Yoichi Miyazaki; Taiji Matsusaka; Naoki Sugano; Hiroyuki Ueda; Tetsuya Kawamura; Makoto Ogura; Takashi Yokoo
Journal:  Clin Exp Nephrol       Date:  2017-08-03       Impact factor: 2.801

3.  Advances in our understanding of the pathogenesis of HIV-1 associated nephropathy in children.

Authors:  Patricio E Ray; Chien-An A Hu
Journal:  Future Virol       Date:  2011-07       Impact factor: 1.831

4.  Soluble VEGF receptor 1 promotes endothelial injury in children and adolescents with lupus nephritis.

Authors:  Monika Edelbauer; Sudhir Kshirsagar; Magdalena Riedl; Heiko Billing; Burkhard Tönshoff; Dieter Haffner; Jörg Dötsch; Gottfried Wechselberger; Lutz T Weber; Elisabeth Steichen-Gersdorf
Journal:  Pediatr Nephrol       Date:  2011-12-07       Impact factor: 3.714

Review 5.  Bevacizumab increases risk for severe proteinuria in cancer patients.

Authors:  Shenhong Wu; Christi Kim; Lea Baer; Xiaolei Zhu
Journal:  J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 10.121

6.  Podocyte and endothelial-specific elimination of BAMBI identifies differential transforming growth factor-β pathways contributing to diabetic glomerulopathy.

Authors:  Han Lai; Anqun Chen; Hong Cai; Jia Fu; Fadi Salem; Yu Li; John C He; Detlef Schlondorff; Kyung Lee
Journal:  Kidney Int       Date:  2020-04-26       Impact factor: 10.612

Review 7.  Anti-vascular endothelial growth factor therapy for diabetic macular edema.

Authors:  David S Boyer; J Jill Hopkins; Jonathan Sorof; Jason S Ehrlich
Journal:  Ther Adv Endocrinol Metab       Date:  2013-12       Impact factor: 3.565

Review 8.  Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.

Authors:  Chelsea C Estrada; Alejandro Maldonado; Sandeep K Mallipattu
Journal:  J Am Soc Nephrol       Date:  2019-01-14       Impact factor: 10.121

9.  Autocrine VEGF signaling is required for vascular homeostasis.

Authors:  Sunyoung Lee; Tom T Chen; Chad L Barber; Maria C Jordan; Jared Murdock; Sharina Desai; Napoleone Ferrara; Andras Nagy; Kenneth P Roos; M Luisa Iruela-Arispe
Journal:  Cell       Date:  2007-08-24       Impact factor: 41.582

10.  A vascular gene trap screen defines RasGRP3 as an angiogenesis-regulated gene required for the endothelial response to phorbol esters.

Authors:  David M Roberts; Amanda L Anderson; Michihiro Hidaka; Raymond L Swetenburg; Cam Patterson; William L Stanford; Victoria L Bautch
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.